{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:01:38Z","timestamp":1770836498615,"version":"3.50.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T00:00:00Z","timestamp":1338768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s12185-012-1116-8","type":"journal-article","created":{"date-parts":[[2012,6,4]],"date-time":"2012-06-04T15:00:49Z","timestamp":1338822049000},"page":"1-9","source":"Crossref","is-referenced-by-count":15,"title":["Biological therapy and the immune system in patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"96","author":[{"given":"Peter","family":"Rohon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,4]]},"reference":[{"key":"1116_CR1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"10","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;10:3343.","journal-title":"Blood"},{"key":"1116_CR2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408.","journal-title":"N Engl J Med"},{"key":"1116_CR3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200.","journal-title":"Leukemia"},{"key":"1116_CR4","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540.","journal-title":"Blood"},{"issue":"24","key":"1116_CR5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u20139.","journal-title":"N Engl J Med."},{"key":"1116_CR6","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055.","journal-title":"Blood"},{"key":"1116_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, et al. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500.","journal-title":"Blood"},{"key":"1116_CR8","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/cncr.25079","volume":"16","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, le Coutre P, Cortes J, et al. Phase I study of INNO-406, a dual Abl\/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer. 2010;16:2665.","journal-title":"Cancer"},{"key":"1116_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2\u00a0years. Blood. 2007;109:58.","journal-title":"Blood"},{"key":"1116_CR10","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1038\/sj.leu.2404807","volume":"21","author":"S Mustjoki","year":"2007","unstructured":"Mustjoki S, Lundan T, Knuutila S, Porkka K. Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia. Leukemia. 2007;21:2363.","journal-title":"Leukemia"},{"key":"1116_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.beha.2008.07.004","volume":"3","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008;3:437.","journal-title":"Best Pract Res Clin Haematol."},{"key":"1116_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","volume":"85","author":"P Rohon","year":"2010","unstructured":"Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387.","journal-title":"Eur J Haematol"},{"key":"1116_CR13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/leu.2008.273","volume":"23","author":"AJ Barrett","year":"2009","unstructured":"Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia. 2009;23:53.","journal-title":"Leukemia"},{"key":"1116_CR14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet. 2005;365:657.","journal-title":"Lancet"},{"key":"1116_CR15","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287.","journal-title":"Leukemia"},{"key":"1116_CR16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0145-2126(97)00152-5","volume":"22","author":"LE Hove van den","year":"1998","unstructured":"van den Hove LE, Vandenberghe P, van Gool SW, Ceuppens JL, et al. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk Res. 1998;22:175.","journal-title":"Leuk Res"},{"key":"1116_CR17","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1182\/blood-2003-01-0150","volume":"102","author":"K Rezvani","year":"2003","unstructured":"Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+\u00a0T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102:2892.","journal-title":"Blood"},{"key":"1116_CR18","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772.","journal-title":"Blood"},{"key":"1116_CR19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1172\/JCI200316398","volume":"111","author":"JJ Molldrem","year":"2003","unstructured":"Molldrem JJ, Lee PP, Kant S. Chronic myeloid leukemia shapes host immunity by a selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003;111:639.","journal-title":"J Clin Invest."},{"issue":"5","key":"1116_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T-cells and immune tolerance. Cell. 2008;133(5):775\u201387.","journal-title":"Cell"},{"key":"1116_CR21","first-page":"1133","volume":"31","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Giannopoulos K. Imatinib impairs the proliferation and function of CD4+\u00a0CD25+\u00a0regulatory T cells in dose dependent manner. Int J Oncol. 2007;31:1133.","journal-title":"Int J Oncol"},{"key":"1116_CR22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14712\/fb2006052030047","volume":"52","author":"E Humlova","year":"2006","unstructured":"Humlova E, Klamova H, Janatkova I. Immunological profiles of patients with chronic myeloid leukemia. State before the start of treatment. Folia Biol. 2006;52:47.","journal-title":"Folia Biol"},{"issue":"3","key":"1116_CR23","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037.","journal-title":"Blood"},{"issue":"17","key":"1116_CR24","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","volume":"115","author":"J Nitin","year":"2009","unstructured":"Nitin J, Reuben JM, Kantarjian H, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009;115(17):3924.","journal-title":"Cancer"},{"issue":"10","key":"1116_CR25","first-page":"1324","volume":"90","author":"J Pinilla-Ibarz","year":"2005","unstructured":"Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, et al. Synthetic peptide analogs derived from bcr\/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90(10):1324.","journal-title":"Haematologica"},{"issue":"14","key":"1116_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000336","volume":"9","author":"S Ariyaratana","year":"2007","unstructured":"Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1.","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"1116_CR27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.x","volume":"80","author":"J Greiner","year":"2008","unstructured":"Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol. 2008;80(6):461.","journal-title":"Eur J Haematol"},{"issue":"2","key":"1116_CR28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7150\/ijms.7.72","volume":"7","author":"M Narita","year":"2010","unstructured":"Narita M, Masuko M, Kurasaki T, et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int J Med Sci. 2010;7(2):72.","journal-title":"Int J Med Sci."},{"issue":"2","key":"1116_CR29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(2):236.","journal-title":"Blood"},{"issue":"17","key":"1116_CR30","first-page":"5226","volume":"13","author":"RJ May","year":"2007","unstructured":"May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+\u00a0and CD8+\u00a0T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(17):5226.","journal-title":"Clin Cancer Res"},{"key":"1116_CR31","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","volume":"111","author":"M Schmitt","year":"2008","unstructured":"Schmitt M, Schmitt A, Rojewski MT. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunologic and clinical response. Blood. 2008;111:1357.","journal-title":"Blood"},{"key":"1116_CR32","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2008-04-150045","volume":"112","author":"C Quintarelli","year":"2008","unstructured":"Quintarelli C, Dotti G, De Angelis B, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008;112:1876.","journal-title":"Blood"},{"key":"1116_CR33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","volume":"5","author":"JC Hern\u00e1ndez-Boluda","year":"2005","unstructured":"Hern\u00e1ndez-Boluda JC, Bellosillo B, Vela MC, et al. Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. Leuk Lymphoma. 2005;5:717.","journal-title":"Leuk Lymphoma"},{"key":"1116_CR34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/107327480901600206","volume":"16","author":"J Pinilla-Ibarz","year":"2009","unstructured":"Pinilla-Ibarz J, Shah B, Dubovsky JA. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Cancer Control. 2009;16:141.","journal-title":"Cancer Control."},{"key":"1116_CR35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/17474086.2.1.81","volume":"2","author":"K Porkka","year":"2009","unstructured":"Porkka K, Mustjoki S, Simonsson B. Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms. Expert Rev Hematol. 2009;2:81.","journal-title":"Expert Rev Hematol."},{"key":"1116_CR36","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol. 2008;127:330.","journal-title":"Clin Immunol."},{"key":"1116_CR37","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/j.1582-4934.2008.00234.x","volume":"12","author":"J Chen","year":"2008","unstructured":"Chen J, Schmitt A, Chen B. Nilotinib hampers the proliferation and function of CD8+\u00a0T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12:2107.","journal-title":"J Cell Mol Med"},{"key":"1116_CR38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366.","journal-title":"Blood"},{"key":"1116_CR39","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","volume":"14","author":"R Weichsel","year":"2008","unstructured":"Weichsel R, Dix C, Wooldridge L. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008;14:2484.","journal-title":"Clin Cancer Res"},{"key":"1116_CR40","doi-asserted-by":"crossref","unstructured":"Hayashi Y, Nakamae H, Katayama T, et al. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib. Leuk Lymphoma. 2012; doi: 10.3109\/10428194.2011.647017 .","DOI":"10.3109\/10428194.2011.647017"},{"key":"1116_CR41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13684730210002319","volume":"4","author":"JM Aswald","year":"2002","unstructured":"Aswald JM, Lipton JH, Aswald S, et al. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther. 2002;4:143.","journal-title":"Cytokines Cell Mol Ther"},{"key":"1116_CR42","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2007.04.016","volume":"8","author":"C Leder","year":"2007","unstructured":"Leder C, Ortler S, Seggewiss R, et al. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol. 2007;8:1266.","journal-title":"Exp Hematol"},{"issue":"8","key":"1116_CR43","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","volume":"111","author":"S Blake","year":"2008","unstructured":"Blake S, et al. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 2008;111(8):4415\u20136.","journal-title":"Blood"},{"key":"1116_CR44","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T, et al. Th e BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer. 2010;127:2119.","journal-title":"Int J Cancer"},{"key":"1116_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135.","journal-title":"Haematologica"},{"key":"1116_CR46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398.","journal-title":"Leukemia"},{"key":"1116_CR47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, et al. Clinical features of dasatinib induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799.","journal-title":"Int J Hematol"},{"key":"1116_CR48","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1182\/blood-2010-05-283127","volume":"116","author":"F Ravandi","year":"2010","unstructured":"Ravandi F. Dasatinib, an immunomodulator? Blood. 2010;116:673.","journal-title":"Blood"},{"key":"1116_CR49","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3109\/10428194.2010.550074","volume":"52","author":"JJ Powers","year":"2011","unstructured":"Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668.","journal-title":"Leuk Lymphoma"},{"key":"1116_CR50","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1182\/blood-2008-04-151969","volume":"113","author":"JJ Melenhorst","year":"2009","unstructured":"Melenhorst JJ, Scheinberg P, Chattopadhyay PK, et al. High avidity myeloid leukemia-associated antigen-specific CD8+\u00a0T cells preferentially reside in the bone marrow. Blood. 2009;113:2238.","journal-title":"Blood"},{"key":"1116_CR51","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2362.2009.02206.x","volume":"39","author":"C Sillaber","year":"2009","unstructured":"Sillaber C, Herrmann H, Bennett K. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140\u00a0mg daily. Eur J Clin Invest. 2009;39:1098.","journal-title":"Eur J Clin Invest"},{"key":"1116_CR52","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, et al. Expansion of highly differentiated CD8(+) T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587.","journal-title":"Leukemia"},{"key":"1116_CR53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.coi.2009.05.012","volume":"21","author":"E Derhovanessian","year":"2009","unstructured":"Derhovanessian E, Larbi A, Pawelec G. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol. 2009;21:440.","journal-title":"Curr Opin Immunol"},{"key":"1116_CR54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/138945011794815301","volume":"12","author":"B Simonsson","year":"2011","unstructured":"Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets. 2011;12:420.","journal-title":"Curr Drug Targets"},{"key":"1116_CR55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/sj.leu.2400723","volume":"11","author":"A Hochhaus","year":"1997","unstructured":"Hochhaus A, Yan XH, Willer A, et al. Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia. Leukemia. 1997;11:933.","journal-title":"Leukemia"},{"key":"1116_CR56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2002-02-0659","volume":"101","author":"A Burchert","year":"2003","unstructured":"Burchert A, Wolfl S, Schmidt M, et al. Interferon alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003;101:259.","journal-title":"Blood"},{"key":"1116_CR57","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, et al. IFN alpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904.","journal-title":"Nature"},{"key":"1116_CR58","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98:3074.","journal-title":"Blood"},{"key":"1116_CR59","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","volume":"20","author":"FX Mahon","year":"2002","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214.","journal-title":"J Clin Oncol"},{"key":"1116_CR60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34.","journal-title":"Oncologist"},{"key":"1116_CR61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8.","journal-title":"Immunol Rev"},{"issue":"3","key":"1116_CR62","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","volume":"8","author":"M Chawla-Sarkar","year":"2003","unstructured":"Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis Int J Program Cell Death. 2003;8(3):237\u201349.","journal-title":"Apoptosis Int J Program Cell Death."},{"key":"1116_CR63","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jir.2011.0028","volume":"31","author":"LM Pfeffer","year":"2011","unstructured":"Pfeffer LM. The role of nuclear factor kappaB in the interferon response. J Interferon Cytokine Res. 2011;31:553.","journal-title":"J Interferon Cytokine Res"},{"key":"1116_CR64","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","volume":"84","author":"R Hehlmann","year":"1994","unstructured":"Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84:4064.","journal-title":"Blood"},{"key":"1116_CR65","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1182\/blood.V79.8.1920.1920","volume":"79","author":"MS Lee","year":"1992","unstructured":"Lee MS, Kantarjian H, Talpaz M, et al. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood. 1992;79:1920.","journal-title":"Blood"},{"key":"1116_CR66","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-114-7-532","volume":"114","author":"M Talpaz","year":"1991","unstructured":"Talpaz M, Kantarjian H, Kurzrock R, et al. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med. 1991;114:532.","journal-title":"Ann Intern Med"},{"key":"1116_CR67","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cytogfr.2007.06.015","volume":"18","author":"LA Kujawski","year":"2007","unstructured":"Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 2007;18:459.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1116_CR68","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","volume":"363","author":"C Preudhomme","year":"2010","unstructured":"Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511.","journal-title":"N Engl J Med"},{"key":"1116_CR69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2010.04.010","volume":"35","author":"FE Nicolini","year":"2011","unstructured":"Nicolini FE, Hayette S, Legros L, et al. Pegylated IFN-alpha2a combined to imatinib mesylate 600\u00a0mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600\u00a0mg daily alone. Leuk Res. 2011;35:80.","journal-title":"Leuk Res"},{"key":"1116_CR70","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","volume":"95","author":"F Palandri","year":"2010","unstructured":"Palandri F, Castagnetti F, Iacobucci I, et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica. 2010;95:1415.","journal-title":"Haematologica"},{"key":"1116_CR71","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, Muller MC, Kostrewa P, et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28:1429.","journal-title":"J Clin Oncol"},{"key":"1116_CR72","doi-asserted-by":"crossref","first-page":"23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS One. 2011;6:23022.","journal-title":"PLoS One"},{"key":"1116_CR73","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/sj.leu.2404892","volume":"21","author":"BN Savani","year":"2007","unstructured":"Savani BN, Mielke S, Adams S, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia. 2007;21:2145.","journal-title":"Leukemia"},{"key":"1116_CR74","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","volume":"113","author":"AS Yong","year":"2009","unstructured":"Yong AS, Keyvanfar K, Hensel N, et al. Primitive quiescent CD34+\u00a0cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood. 2009;113:875.","journal-title":"Blood"},{"key":"1116_CR75","doi-asserted-by":"crossref","first-page":"11770","DOI":"10.1371\/journal.pone.0011770","volume":"5","author":"S Kanodia","year":"2010","unstructured":"Kanodia S, Wieder E, Lu S, et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010;5:11770.","journal-title":"PLoS One"},{"key":"1116_CR76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.molmed.2009.04.005","volume":"15","author":"J Rey","year":"2009","unstructured":"Rey J, Veuillen C, Vey N, et al. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med. 2009;15:275.","journal-title":"Trends Mol Med"},{"key":"1116_CR77","doi-asserted-by":"crossref","first-page":"16700","DOI":"10.1371\/journal.pone.0016700","volume":"6","author":"GM Siegers","year":"2011","unstructured":"Siegers GM, Felizardo TC, Mathieson AM, et al. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic ph leukemia model. PLoS One. 2011;6:16700.","journal-title":"PLoS One"},{"key":"1116_CR78","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633.","journal-title":"Trends Immunol"},{"key":"1116_CR79","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.imbio.2010.09.012","volume":"216","author":"MP Correia","year":"2011","unstructured":"Correia MP, Costa AV, Uhrberg M, et al. IL-15 induces CD8+\u00a0T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology. 2011;216:604.","journal-title":"Immunobiology"},{"key":"1116_CR80","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","volume":"1","author":"Y Chen","year":"2010","unstructured":"Chen Y, Peng C, Li D, et al. Molecular and cellular bases of chronic myeloid leukemia. Protein cell. 2010;1:124.","journal-title":"Protein cell"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1116-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1116-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T08:02:32Z","timestamp":1743235352000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1116-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,4]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1116-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,4]]}}}